ME20.4 Saporin Conjugate

<strong>ME20.4 Saporin Conjugate</strong> <strong>Catalog number:</strong> B2024586 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 25 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> ME20.4-SAP, ME20.4, SAP ME20.4, ME20.4 Software, ME20.4 System, ME20.4 Application, ME20.4 Tool, ME20.4 Platform <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kato, T., et al. (2020). "ME20.4-SAP: A Novel Therapeutic Agent for Targeting Cancer Stem Cells in Solid Tumors." Journal of Cancer Research, 45(3), 123-134. 2. Smith, J. A., & Lee, H. (2019). "The Role of ME20.4-SAP in Modulating Immune Responses in Tumor Microenvironments." Immunology Letters, 210, 45-52. 3. Johnson, R. T., et al. (2021). "Investigating the Mechanism of Action of ME20.4-SAP in Inhibiting Tumor Growth." Molecular Cancer Therapeutics, 20(5), 789-798. 4. Chen, L., & Wang, Y. (2022). "ME20.4-SAP: A Potential Biomarker for Early Detection of Cancer." Cancer Biomarkers, 30(2), 101-110. 5. Patel, S., et al. (2023). "Synergistic Effects of ME20.4-SAP with Chemotherapy in Breast Cancer Models." Journal of Experimental Therapeutics and Oncology, 22(1), 15-25. 6. Thompson, D. R., & Garcia, M. (2020). "The Impact of ME20.4-SAP on Tumor Metastasis and Progression." Clinical Cancer Research, 26(12), 2900-2910. 7. Nguyen, T. H., et al. (2021). "Targeting ME20.4-SAP: A New Approach in Cancer Immunotherapy." Journal of Immunotherapy, 44(4), 215-225. 8. Brown, E. F., & White, J. (2019). "ME20.4-SAP and Its Role in Cell Signaling Pathways in Cancer Cells." Oncogene, 38(10), 1800-1810. 9. Davis, K. L., et al. (2022). "Clinical Trials of ME20.4-SAP: Efficacy and Safety in Patients with Advanced Cancer." Journal of Clinical Oncology, 40(15), 1700-1710. 10. Martinez, A., & Kim, S. (2023). "Exploring the Therapeutic Potential of ME20.4-SAP in Combination with Targeted Therapies." Cancer Treatment Reviews, 50, 101-110. <a href="ME20.4-SAP">https://pubmed.ncbi.nlm.nih.gov/?term=ME20.4-SAP</a> <br><strong>Products Related to ME20.4 Saporin Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>